TRIB3 and acute promyelocytic leukemia: Overall, arsenic/ATRA treatment enhances TRIB3 abundance in APL cells, and TRIB3 interacts with PPARγ to impede the heterodimer formation of PPARγ and RXR, inhibiting PPARγ transcriptional activity and abnormal lipid metabolism in APL cells (Figure 7N).